The Facts:

• The NIRD® will image 95-98% of acute Subdural and Epidural hematomas identified on CT

• Subdural and Epidural hematomas represent 90-95% of all hemorrhages diagnosed in TBI

• 90-93% of CT scans ordered for head injury are negative for bleeding

The Problem

TBI is a major global health issue, affecting 69 million people annually and leading to significant costs. It is a leading cause of death for children and particularly impacts individuals under 45. Furthermore, an aging population with increased susceptibility to falls will likely compound the prevalence and impact of TBI in the coming years.

The Solution

Archeoptix has developed the NIRD®, a lightweight, portable device that provides CT accuracy in determining the severity of Traumatic Brain Injury (TBI) and other causes of brain bleeds. It is not a replacement for CT—we bring CT capabilities to the point of injury, where it matters most.

Portable and Easy to Use

The NIRD® weighs 8.5 lbs, is non-invasive, emits no radiation, and provides valuable information about other conditions, including hemorrhagic and ischemic stroke. Like no other TBI device/technology in the world, the NIRD® provides imaging that can be used by healthcare professionals with different levels of experience/training.

Improves Outcomes By Expediting Transport to Definitive Care

The NIRD® offers a solution to front-line healthcare workers by accurately detecting 95-98% of acute subdural and epidural hematomas, the most common TBI hemorrhages. This portable, easy-to-use device allows for rapid assessment and can be used in various settings, improving patient outcomes and reducing healthcare costs.

Catch it early. Expedite care. Improve outcomes. Reduce Costs.